Mid-Afternoon Market Update: Dow Surges Over 100 Points; NextGen Healthcare Shares Plunge
Toward the end of trading Thursday, the Dow traded up 0.34% to 34,439.88 while the NASDAQ rose 0.23% to 13,770.24. The S&P also rose, gaining 0.23% to ...
Stay updated with breaking news from Rezolute Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Toward the end of trading Thursday, the Dow traded up 0.34% to 34,439.88 while the NASDAQ rose 0.23% to 13,770.24. The S&P also rose, gaining 0.23% to ...
Published: May 17, 2021 REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalance, today announced that management will present at the Oppenheimer Rare and Orphan Disease Summit. The presentation will be available on-demand starting at 8:00 AM ET on Friday, May 21, 2021. A webcast of the presentation will be available for 90 days on the “IR Calendar” page within the Investors section of the Rezolute website at https://ir.rezolutebio.com/ir...
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) were trading at new all-time high levels on Wednesday afternoon on concerns that rival Allergan (NYSE: AGN) may have problems moving its unnamed vision-loss drug into late-stage trials. The speculation is that Allergan believes it may have... Read More... Don't Miss Any Updates! News Directly in Your Inbox Subscribe to:
Published: Mar 10, 2021 Recognized revenue of $29.4 million Six assets in the Company’s milestone and royalty portfolio advanced to Phase 2 clinical development Completed $24.6 million Series A Perpetual Preferred Stock offering paying a 8.625% dividend Ended 2020 with $84.2 million in cash EMERYVILLE, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced its fourth quarter and full-year 2020 financial results and business highlights. “Our success in 2020 is a direct reflection of our strategy at work. As a result of the commitment by our partner...
Published: Mar 01, 2021 By Heather McKenzie February 28 marked Rare Disease Day, and biotech companies gathered together to raise awareness, advocate for improved access to treatment and let patients know how they are pivoting to improve patient care and access during the COVID-19 pandemic and beyond. Rezolute Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for patients with metabolic and orphan diseases, was just beginning a Phase IIb study of its lead candidate, RZ358, for Congenital hyperinsulinism (HI), when the chaos struck. “We have hospitals...